Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBITDA Margin (2016 - 2025)

Anaptysbio (ANAB) has disclosed EBITDA Margin for 10 consecutive years, with 45.77% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 13472.0% year-over-year to 45.77%, compared with a TTM value of 6.51% through Dec 2025, up 24135.0%, and an annual FY2025 reading of 5.78%, up 15212.0% over the prior year.
  • EBITDA Margin was 45.77% for Q4 2025 at Anaptysbio, up from 30.33% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 45.77% in Q4 2025 and bottomed at 3945.05% in Q1 2022.
  • Average EBITDA Margin over 5 years is 1041.04%, with a median of 437.45% recorded in 2024.
  • Peak annual rise in EBITDA Margin hit 272732bps in 2022, while the deepest fall reached -376235bps in 2022.
  • Year by year, EBITDA Margin stood at 3240.36% in 2021, then skyrocketed by 84bps to 513.04% in 2022, then increased by 12bps to 451.5% in 2023, then soared by 80bps to 88.95% in 2024, then surged by 151bps to 45.77% in 2025.
  • Business Quant data shows EBITDA Margin for ANAB at 45.77% in Q4 2025, 30.33% in Q3 2025, and 174.27% in Q2 2025.